Tumor response to immunochemotherapy may spare some head and neck cancer patients radical surgery
In patients with HPV‑negative locally advanced resectable head and neck squamous cell carcinoma (HNSCC), neoadjuvant immunochemotherapy (ICT) induced ≥50 % tumor regression in 90 % of 47 evaluable patients, allowing reduced‑volume surgery, resulting in a 2‑year disease‑free survival of 90 % and complete preservation of laryngeal function. Higher PD‑L1 Combined Positive Score (>20) was associated with 65 % pathological complete response.
This study demonstrates that response‑adapted surgery after neoadjuvant ICT can provide excellent disease control and organ preservation in HPV‑negative HNSCC, informing future trials that may transform treatment paradigms for this high‑risk patient group.
Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Kapcsolódó jelek
- Spatial Profiling of the Head and Neck Squamous Cell Carcinoma Microenvironment: Reshaping Our Understanding and Therapeutic Opportunities
- Understanding and overcoming innate and acquired MAPK inhibition resistance in anaplastic thyroid cancer
- Review Systemic therapy in the curative treatment of head and neck squamous cell cancer: a systematic review
- Preclinical models in head and neck squamous cell carcinoma
- CAR-Based Cell Therapy in Head and Neck Cancer: A Comprehensive Review on Clinical Applicability